Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...

Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said.

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

RSV is a highly contagious virus that affects people of all ages, from infants to adults. Its symptoms often mimic those of influenza or COVID-19, making it hard to differentiate between these ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

Respiratory syncytial virus, or RSV, isn't always top of mind during the colder months. It's often overshadowed by flu season, or winter waves of COVID-19. But the reality is, this viral ...

Covid-19 levels in the United States are high and rising, flu season is approaching quickly and RSV cases are already ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

Often dismissed as just another common cold, RSV can be deadly, especially for infants and older people. Hannah and her twin ...